Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

MRK | Merck & Co Inc

Healthcare | Drug Manufacturers - General | USA | NYSE

Index	DJIA, S&P 500	P/E	86.78	EPS (ttm)	1.21	Insider Own	0.09%	Shs Outstand	2.54B	Perf Week	-1.83%
Market Cap	267.43B	Forward P/E	12.45	EPS next Y	8.47	Insider Trans	-18.64%	Shs Float	2.54B	Perf Month	-4.37%
Income	3.11B	PEG	7.26	EPS next Q	1.95	Inst Own	78.02%	Short Float / Ratio	0.55% / 2.00	Perf Quarter	-7.00%
Sales	57.35B	P/S	4.66	EPS this Y	-59.64%	Inst Trans	0.64%	Short Interest	13.88M	Perf Half Y	-1.44%
Book/sh	15.24	P/B	6.92	EPS next Y	180.50%	ROA	2.94%	Target Price	124.78	Perf Year	21.45%
Cash/sh	2.53	P/C	41.64	EPS next 5Y	11.95%	ROE	7.59%	52W Range	85.29 - 119.65	Perf YTD	-5.01%
Dividend	2.97	P/FCF	24.70	EPS past 5Y	45.70%	ROI	4.28%	52W High	-11.92%	Beta	0.34
Dividend %	2.82%	Quick Ratio	1.03	Sales past 5Y	8.48%	Gross Margin	71.26%	52W Low	23.57%	ATR	1.62
Employees	69000	Current Ratio	1.28	Sales Q/Q	1.78%	Oper. Margin	12.87%	RSI (14)	38.48	Volatility	1.21% 1.43%
Optionable	Yes	Debt/Eq	0.95	EPS Q/Q	-	Profit Margin	5.42%	Rel Volume	0.78	Prev Close	105.84
Shortable	Yes	LT Debt/Eq	0.88	Earnings	Aug 01 BMO	Payout	49.02%	Avg Volume	6.92M	Price	105.39
Recom	1.69	SMA20	-2.49%	SMA50	-2.15%	SMA200	-4.13%	Volume	5,400,486	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70
Dec-13-21	Downgrade	UBS	Buy → Neutral	$98 → $76
Dec-09-21	Initiated	Wells Fargo	Overweight	$90
Dec-07-21	Downgrade	Guggenheim	Buy → Neutral
Nov-29-21	Downgrade	Citigroup	Buy → Neutral	$105 → $85
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$91

Show Previous Ratings

Sep-25-23 12:06PM	Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies (Zacks)
09:56AM	10 Best Ways to Prevent Type 2 Diabetes (Insider Monkey)
Sep-22-23 03:47PM	20 Most Innovative Companies in America (Insider Monkey)
06:00AM	Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (Business Wire)
Sep-21-23 08:26AM	Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag (Zacks)
10:45AM	Loading…
Sep-20-23 10:45AM	FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma (Zacks)
06:45AM	FDA Grants Priority Review to Mercks Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer (Business Wire)
Sep-19-23 06:45AM	FDA Accepts for Priority Review Mercks Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) (Business Wire)
06:22AM	UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination (Reuters)
Sep-18-23 10:50AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
08:29AM	Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer (Zacks)
Sep-17-23 05:36PM	17 Best Low Risk Investments in 2023 (Insider Monkey)
Sep-15-23 09:10AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy (Business Wire)
Sep-14-23 07:03AM	Merck & Co Inc (MRK): A Comprehensive Analysis of its Dividend Performance and Sustainability (GuruFocus.com)
Sep-13-23 05:50PM	Merck (MRK) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:16PM	Loading…
Sep-12-23 05:16PM	12 Best Pharma ETFs (Insider Monkey)
Sep-11-23 11:41AM	Moderna enters cancer collaboration with Immatics worth $1.8B (American City Business Journals)
08:06AM	Reasons for the Rise of Merck & Co. (MRK) in Q2 (Insider Monkey)
07:45AM	Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH) (Business Wire)
Sep-08-23 03:26PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
Sep-07-23 07:08AM	7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth (InvestorPlace)
06:45AM	European Commission Expands Mercks ERVEBO® [Ebola Zaire Vaccine, (rVSVG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older (Business Wire)
Sep-06-23 07:03AM	15 Stocks to Buy with Steady Dividends (Insider Monkey)
Sep-05-23 08:00AM	Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics (Business Wire)
06:45AM	Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-31-23 11:03PM	Goldman Sachs Growth Stocks: Top 12 Stocks (Insider Monkey)
11:22AM	Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list (Yahoo Finance)
Aug-30-23 01:25PM	Medicare's drug pricing list didn't impact company stocks, here's why (Yahoo Finance)
01:25PM	Medicare's drug pricing list didn't impact company stocks here's why (Yahoo Finance)
11:51AM	Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer (Zacks)
11:33AM	Loading…
11:33AM	Medicare price negotiation list: What it means for pharma companies (Yahoo Finance Video)
Aug-29-23 05:12PM	Expensive Drugs Targeted for First U.S. Price Negotiations (The Wall Street Journal)
03:26PM	Eli Lilly and Other Pharma Stocks Are Ignoring Medicares 10 Drug List (Barrons.com)
09:45AM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca (Zacks)
09:24AM	Best Buy results, Medicare negotiations list, Hurricane Idalia: Top stories (Yahoo Finance Video)
08:55AM	The 10 Drugs Medicare Can Negotiate Were Just Announced. These Pharma Stocks Are Impacted. (Barrons.com)
07:46AM	Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations (Yahoo Finance)
06:50AM	European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS 1) (Business Wire)
06:45AM	Merck to Participate in the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-28-23 11:40AM	Unveiling Merck (MRK)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
10:45AM	Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study (Zacks)
08:38AM	Oncology Market's Huge Potential Puts These Stocks in Focus (Zacks)
Aug-27-23 09:47AM	13 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-25-23 11:07AM	AstraZeneca files lawsuit against U.S. over drug pricing (Yahoo Finance Video)
06:41AM	UPDATE 2-Merck, Eisai discontinue late-stage study for combo cancer therapy (Reuters)
06:30AM	Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616 (Business Wire)
06:22AM	Merck-Eisai's cancer therapy fails to meet main goal in late-stage study (Reuters)
06:15AM	Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Business Wire)
Aug-24-23 04:53PM	AARP to join US government in two more lawsuits over Medicare drug pricing negotiations (Yahoo Finance)
04:53PM	AARP joins US government in two more lawsuits over Medicare drug pricing negotiations (Yahoo Finance)
06:45AM	LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (Business Wire)
05:00AM	The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb (Zacks)
Aug-23-23 12:56PM	Top Stock Reports for Merck, Philip Morris & QUALCOMM (Zacks)
11:33AM	Merck (MRK): A Fairly Valued Player in the Pharmaceutical Industry (GuruFocus.com)
09:58AM	Billionaire Ken Fisher and Corporate Insiders Are Betting On These Stocks (Insider Monkey)
09:24AM	25 Most Innovative Companies Of All Time (Insider Monkey)
Aug-22-23 05:46PM	12 Most Undervalued Blue Chip Stocks to Buy According to Hedge Funds (Insider Monkey)
01:24PM	Health care stocks: What the market technicals show (Yahoo Finance Video)
08:38AM	11 Best Weight Loss Stocks To Invest In (Insider Monkey)
Aug-21-23 04:18PM	Moderna, Pfizer stocks rise amid new Covid variants (Yahoo Finance Video)
01:41PM	Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals (Zacks)
12:58PM	Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS (Yahoo Finance)
Aug-18-23 04:11PM	AARP urges courts to keep drug pricing talks on track (Yahoo Finance Video)
02:50PM	Goldman Sachs Dividend Stocks: Top 12 Stock Picks (Insider Monkey)
06:45AM	Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (Business Wire)
Aug-16-23 08:00AM	Merck Employee Talks Pride, Pediatrics and Parenting (ACCESSWIRE)
Aug-15-23 07:58AM	Conservative Stock Portfolio: 10 Best Stocks To Buy (Insider Monkey)
07:35AM	15 Worst Performing Blue Chip Stocks in 2023 (Insider Monkey)
07:00AM	Get In on This Skin Disease Drug Before Big Pharma Does (The Wall Street Journal)
Aug-11-23 03:44PM	Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare (InvestorPlace)
Aug-10-23 09:20PM	The 3 Best ESG Stocks to Buy in August (InvestorPlace)
06:08AM	The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake (American City Business Journals)
Aug-09-23 07:00PM	The 3 Best Healthcare Stocks to Buy in August (InvestorPlace)
Aug-08-23 08:15AM	Merck Is Harnessing Innovation To Reach Indigenous Communities (ACCESSWIRE)
Aug-07-23 08:30AM	Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial (PR Newswire)
Aug-03-23 10:21PM	Q2 2023 Moderna Inc Earnings Call (Thomson Reuters StreetEvents)
06:45AM	U.S. FDA Approves Mercks ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older (Business Wire)
Aug-01-23 03:10PM	Pfizer sees mixed quarterly results on uncertain COVID outlook (Yahoo Finance)
03:10PM	Pfizer reports mixed quarterly results on uncertain COVID outlook (Yahoo Finance)
02:26PM	Merck upgrades guidance on stronger 2023 outlook as COVID business declines (Yahoo Finance)
02:00PM	Merck (MRK) Q2 2023 Earnings Call Transcript (Motley Fool)
12:28PM	Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View (Zacks)
12:03PM	Stock market today: Dow edged higher but S&P stumbled after deluge of earnings (Investing.com)
11:19AM	S&P 500 stumbles pressured by cruise stocks as earnings season heats up (Investing.com)
11:07AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
10:01AM	Merck revenue rises, Pfizer hit by falling COVID product demand (Yahoo Finance Video)
08:59AM	Midday movers: Arista Networks, Caterpillar, ZoomInfo Technologies and more (Investing.com)
07:23AM	Merck Posts Narrower-Than Expected Loss, Lifts Sales Outlook on Keytruda Boost (TheStreet.com)
07:03AM	U.S. stocks were wobbling as investors take in megacap earnings (Investing.com)
06:49AM	UPDATE 3-Merck raises 2023 sales forecast as top drugs beat Street estimates (Reuters)
06:40AM	Merck: Q2 Earnings Snapshot (AP Finance)
06:38AM	Merck Posts Narrower Q2 Loss, Lifts Sales Forecast On Keytruda Boost (TheStreet.com)
06:37AM	Merck beats quarterly sales estimate on top drugs' strength (Reuters)
06:30AM	Merck posts narrower-than-expected loss as sales of top drugs beat Street estimates (Reuters)
06:30AM	Merck Announces Second-Quarter 2023 Financial Results (Business Wire)
Jul-29-23 07:13AM	11 Best Magic Formula Stocks to Buy Now (Insider Monkey)
Jul-28-23 06:45AM	Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer (Business Wire)
06:14AM	Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
06:00AM	FOCUS-Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
01:09AM	13 Safe Stocks To Invest In (Insider Monkey)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MIZELL STEVEN	EVP, Chief HR Officer	Aug 14	Sale	109.01	4,250	463,292	22,935	Aug 15 04:08 PM
Guindo Chirfi	Chief Marketing Officer	Aug 03	Option Exercise	105.70	36,901	3,900,436	38,342	Aug 04 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 03	Sale	105.49	4,500	474,701	27,185	Aug 04 04:06 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02	Sale	107.37	59	6,335	0	Aug 03 04:08 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02	Sale	107.37	30	3,221	20,569	Aug 03 04:08 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Option Exercise	65.24	16,824	1,097,552	61,585	May 05 04:54 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04	Option Exercise	118.22	907	107,226	20,207	May 05 05:09 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04	Option Exercise	118.22	885	104,625	19,476	May 05 05:06 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 04	Option Exercise	118.22	813	96,113	5,421	May 05 05:01 PM
Zachary Jennifer	EVP, General Counsel	May 04	Sale	117.59	19,141	2,250,834	35,128	May 05 05:13 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Sale	117.53	15,875	1,865,843	45,710	May 05 04:54 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Option Exercise	75.55	52,000	3,928,540	73,085	May 05 05:19 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 03	Option Exercise	117.89	803	94,666	45,363	May 05 04:54 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 03	Option Exercise	117.89	689	81,226	4,844	May 05 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Sale	119.01	53,400	6,355,056	31,685	May 05 05:19 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Option Exercise	56.04	6,035	338,201	18,568	May 03 04:29 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Sale	116.82	7,509	877,222	11,059	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Option Exercise	56.04	75,436	4,227,433	229,929	May 02 11:37 AM
Li Dean Y	Executive VP & President, MRL	May 01	Option Exercise	115.47	1,062	122,629	20,995	May 03 04:10 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 01	Option Exercise	115.47	930	107,387	44,879	May 03 04:24 PM
Litchfield Caroline	EVP & CFO	May 01	Option Exercise	115.47	866	99,997	32,118	May 03 04:07 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 01	Option Exercise	115.47	866	99,997	19,727	May 03 03:54 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 01	Option Exercise	115.47	866	99,997	18,901	May 03 03:00 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 01	Option Exercise	115.47	643	74,247	4,376	May 03 03:11 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 01	Option Exercise	115.47	577	66,626	12,731	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Sale	116.03	75,436	8,752,749	154,493	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Option Exercise	56.04	143,329	8,032,157	415,146	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Option Exercise	62.07	66,163	4,106,737	220,656	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Sale	114.93	143,329	16,472,845	271,817	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Sale	115.00	66,163	7,608,844	154,493	May 02 11:37 AM
Romanelli Joseph	President, Human Health Int?l	Apr 26	Buy	113.68	3	341	20,599	Jun 30 04:04 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Option Exercise	59.02	134,055	7,911,405	134,055	Apr 14 04:34 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Sale	115.07	134,055	15,425,068	0	Apr 14 04:34 PM
Romanelli Joseph	President, Human Health Int?l	Mar 24	Sale	104.65	35	3,663	20,596	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Mar 20	Buy	105.47	136	14,344	20,631	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Feb 21	Buy	109.20	11	1,201	20,495	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Feb 15	Sale	108.22	5,000	541,100	20,284	Feb 16 11:58 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 13	Sale	109.10	1,815	198,017	33,085	Feb 14 10:03 AM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 10	Option Exercise	106.72	1,205	128,598	12,505	Feb 13 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 09	Sale	107.00	5,000	535,006	34,900	Feb 10 11:28 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 06	Sale	104.25	4,436	462,473	39,900	Feb 08 10:27 AM
Zachary Jennifer	EVP, General Counsel	Feb 03	Option Exercise	56.04	75,436	4,227,433	129,356	Feb 06 04:21 PM
Zachary Jennifer	EVP, General Counsel	Feb 03	Sale	103.17	75,436	7,782,762	53,920	Feb 06 04:21 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Option Exercise	53.06	83,994	4,456,722	113,494	Jan 11 04:22 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Sale	112.29	83,994	9,431,915	29,500	Jan 11 04:22 PM
Romanelli Joseph	President, Human Health Int?l	Dec 19	Buy	109.04	7	763	20,484	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 13	Buy	110.96	56	6,214	20,477	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 06	Buy	109.39	30	3,282	20,421	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 05	Buy	109.54	107	11,721	20,391	Jun 30 04:04 PM
Romanelli Joseph	President, Human Health Int?l	Dec 02	Buy	109.67	59	6,471	59	Jun 30 04:04 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 10	Option Exercise	0.00	15,000	0	47,144	Nov 10 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 10	Sale	101.42	15,000	1,521,278	32,144	Nov 10 05:01 PM
Davis Robert M	CEO & President	Nov 09	Option Exercise	0.00	167,613	0	415,206	Nov 10 04:42 PM
Davis Robert M	CEO & President	Nov 09	Sale	102.44	167,613	17,169,840	247,593	Nov 10 04:42 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09	Sale	103.21	1,795	185,262	16,731	Nov 10 04:44 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 08	Option Exercise	0.00	20,000	0	52,144	Nov 10 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 08	Sale	101.00	20,000	2,020,000	32,144	Nov 10 05:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 07	Option Exercise	0.00	52,743	0	64,087	Nov 07 04:09 PM
FRAZIER KENNETH C	Executive Chair	Nov 07	Option Exercise	0.00	235,769	0	936,422	Nov 08 04:56 PM
FRAZIER KENNETH C	Executive Chair	Nov 07	Sale	99.55	235,769	23,471,433	700,653	Nov 08 04:56 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 07	Sale	99.47	45,561	4,531,980	18,526	Nov 07 04:09 PM
FRAZIER KENNETH C	Executive Chair	Nov 04	Option Exercise	0.00	235,000	0	935,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 04	Sale	98.61	235,000	23,174,230	700,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 03	Option Exercise	0.00	235,000	0	935,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 03	Sale	98.71	235,000	23,197,888	700,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 02	Option Exercise	0.00	300,000	0	1,000,653	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 02	Sale	99.91	300,000	29,971,843	700,653	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 01	Option Exercise	0.00	300,000	0	1,006,283	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 01	Sale	99.81	300,000	29,942,864	706,283	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Oct 31	Option Exercise	0.00	300,000	0	1,006,283	Nov 01 04:38 PM
FRAZIER KENNETH C	Executive Chair	Oct 31	Sale	100.75	300,000	30,224,092	706,283	Nov 01 04:38 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30	Option Exercise	100.77	913	92,003	11,794	Nov 01 04:30 PM
Zachary Jennifer	EVP, General Counsel	Oct 28	Option Exercise	0.00	148,647	0	203,295	Nov 01 04:28 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Oct 28	Option Exercise	0.00	164,557	0	301,534	Nov 01 05:04 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Oct 28	Option Exercise	0.00	100,292	0	145,900	Nov 01 05:07 PM
Karachun Rita A	Sr. VP Fince-Global Controller	Oct 28	Option Exercise	0.00	31,997	0	73,100	Nov 01 04:36 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 28	Option Exercise	0.00	17,000	0	57,144	Nov 01 04:33 PM
FRAZIER KENNETH C	Executive Chair	Oct 28	Option Exercise	0.00	567,084	0	1,273,367	Nov 01 04:38 PM
FRAZIER KENNETH C	Executive Chair	Oct 28	Sale	100.28	567,084	56,866,272	706,283	Nov 01 04:38 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Oct 28	Sale	100.26	164,557	16,499,094	136,977	Nov 01 05:04 PM
Zachary Jennifer	EVP, General Counsel	Oct 28	Sale	99.38	165,255	16,422,893	38,040	Nov 01 04:28 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Oct 28	Sale	100.10	100,292	10,039,380	45,608	Nov 01 05:07 PM
Karachun Rita A	Sr. VP Fince-Global Controller	Oct 28	Sale	100.34	31,997	3,210,685	41,103	Nov 01 04:36 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 28	Sale	99.63	25,000	2,490,720	32,144	Nov 01 04:33 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 28	Sale	100.21	3,633	364,065	10,881	Nov 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK | Merck & Co Inc

Upgrade your FINVIZ experience